NK521 Cell clinical trials
NK521 Cell is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Early Phase 1. The lead sponsor is Base Therapeutics (Shanghai) Co., Ltd. The most-studied condition is Hepatocellular Carcinoma (HCC).
Patient leaflets for NK521 Cell
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of NK521 Cell
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
NCT07561437 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Early Phase 1 | Recruiting | Base Therapeutics (Shanghai) Co., Ltd | China |
|
NK521 in the Treatment of Advanced Solid Tumors
NCT07657416 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
|
Early Phase 1 | Not yet open | Base Therapeutics (Shanghai) Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with NK521 Cell
4 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Base Therapeutics (Shanghai) Co., Ltd | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about NK521 Cell trials
How many clinical trials are testing NK521 Cell?
2 current trials in our China register name NK521 Cell as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are NK521 Cell trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors NK521 Cell clinical trials?
The lead sponsor is Base Therapeutics (Shanghai) Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NK521 Cell works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NK521 Cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NK521 Cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.